Tackling Rare Diseases


Cambridge Healthtech Institute 第3届
罕见疾病的治疗
新医药品模态、新化验及模型、新治疗策略

第15届Discovery on Target其中一环

本座谈会以罕见疾病治疗为主题,致力于治疗药开发及产品化的主要研究人员、医生、企业主管、专家将齐聚一堂。座谈会将聚焦克服新模态的治疗药物开发、创新技术利用、转译研究相关课题方法等议题,来自不同专业背景的与会者将讨论该领域的潜在机会。在这场独特的整日座谈会中,将能够与来自全球各地的专家交流意见、建立合作关系,是一个十分宝贵的机会。

Final Agenda


RECOMMENDED ALL ACCESS PACKAGE:

· September 25 Symposium: Constrained Peptides and Macrocyclics

· September 25 Short Course: Applications of Functional Screening Using CRISPR and RNAi

· September 26-27 Conference: CRISPR for Disease Modeling and Target Discovery

· September 27-28 Conference: Emerging Oligonucleotide Therapeutics

· September 27 Short Course: CRISPR-Based Gene Editing for Targeted Therapies

· September 28-29 Symposium: Tackling Rare Diseases


Thursday, September 28

4:00 pm Registration

Regulatory Perspectives & Innovative Strategies

5:25 Welcome Remarks

Tanuja Koppal, Ph.D., Conference Director, Cambridge Healthtech Institute

5:30 Chairperson's Remarks

Adam Hutchings, Director, Dolon Ltd.

5:40 FEATURED PRESENTATION: Rare Disease Landscape: Fact Sheets in Research and Service Delivery

Segolene Ayme, Emeritus Director of Research, French Institute of Health and Medical Research (INSERM); Expert in Residence for Rare Diseases, Brain and Spine Institute, Paris; and Editor-in-Chief, Orphanet Journal of Rare Diseases

The importance of rare diseases, as a driver for innovation in science and in healthcare organization, is now established and many indicators demonstrate that incentives have been instrumental in shaping the current situation. However, clouds are accumulating as many stakeholders question the affordability of the new diagnostic and therapeutic options. Joined efforts of the various stakeholders are necessary to keep this sector alive.

6:10 Overview of Key Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)

Adam Hutchings, Director, Dolon Ltd.

To help improve the speed and consistency of patient access to orphan medicines, a European multi-stakeholder group of rare disease experts, ORPH-VAL, has proposed a set of common principles to improve the consistency of decision making for orphan drugs and balance the needs of innovators and payers. Policymakers and rare disease stakeholders should engage with these recommendations, explore areas where local P&R systems diverge from the principles, and identify and enact potential reforms, all with the goal of improving overall access to medicines for patients with rare diseases.

6:40 Close of Day

Friday, September 29

8:00 am Registration and Morning Coffee

Exploring Phenotypic Screening, Stem Cell Models and More

8:30 Chairperson's Remarks

Ronald Alfa, M.D., Ph.D., Vice President, Discovery & Product, Recursion Pharmaceuticals

8:40 Development of Multi-Modal Small Molecule Therapeutics for the Neuronal Ceroid Lipofuscinoses

Paul Trippier, Ph.D., Assistant Professor, Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center

The neuronal ceroid lipofuscinoses (NCLs), although rare, are the most common neurodegenerative disorders of childhood. We have developed a patient-specific induced pluripotent stem cell (iPSC) model of CLN3 disease (Batten disease) in which we have screened a library of proprietary small molecules. This phenotypic screen has identified neuroprotective small molecules with translational activity in patient specific cells. Our mechanism of action studies reveal a novel multi-modal mechanism of action suitable for treating other neurodegenerative disorders.

9:10 Disease Modeling: Even Rare Diseases Are Complex

Michael Liebman, Ph.D., Managing Director, IPQ Analytics, LLC; Adjunct Professor of Pharmacology and Physiology, Drexel College of Medicine

Pediatric ARDS, a rare disease, presents challenges in diagnosis and treatment because it is a syndrome and exhibits significant heterogeneity in patients and their symptoms in spite of the specific diagnosis. The Nathaniel Adamczyk Foundation has been involved in developing a clinical research and decision support platform to catalyze the formation of a community that focuses on these challenges and enables hypothesis development and testing with unique analytic tools.

9:40 Massive Parallelization of Rare Disease Drug Discovery

Ronald Alfa, M.D., Ph.D., Vice President, Discovery & Product, Recursion Pharmaceuticals

Recursion has developed a target agnostic discovery platform that combines artificial intelligence with automated biology for massive parallelization of high-throughput drug screening. In this session, I will describe our platform and provide a case study of drugs identified for a rare genetic disease.

10:10 Networking Coffee Break

New Therapeutic Modalities

10:40 A New Approach to Block ERAD and Reduce the Degradation of Partially Misfolded Mutant Proteins

Clifford Lingwood, Ph.D., Senior Scientist, Molecular Structure and Function, Hospital for Sick Children

Many genetic diseases result from the ER associated degradation (ERAD) of the partiallly misfolded mutant protein. Several bacterial/plant subunit toxins (e.g. cholera, Shiga toxin) hijack this pathway to achieve A subunit cytosolic access by using the same ER translocon. By A subunit mutagenesis we generate a benign toxoid which remains an ER translocon substrate, and as such is a temporary, competitive inhibitor of the ER translocon which partially rescues the deficiency disease phenotype in cell culture (e.g. F508delta CFTR of CF, N370S GCC of Gaucher's).

11:10 The Potential of RNAi in Orphan Diseases - The Alpha 1 Anti-Trypsin Liver Disease Example

Dawn Christianson, Ph.D., Senior Program Manager, Arrowhead Research Corporation

Alpha 1 anti-trypsin deficiency is named a deficiency state because it is usually caused by a gene mutation which prevents the synthesized protein from exiting the liver, resulting in emphysema. However, in the liver it is a storage disease and with better pulmonary care and survival, patients are dying from liver disease or requiring transplant. RNAi is an apt approach to treating the liver disease, as evidenced by studies in animals and humans.

11:40 Sponsored Presentation (Opportunity Available)

12:10 pm Enjoy Lunch on Your Own

EXPLOITING TARGETED GENOMICS & DELIVERY TOOLS

1:45 Chairperson's Remarks

Ryan Hartmaier, Ph.D., Senior Scientist, Cancer Genomics, Foundation Medicine, Inc.

1:50 Engineering Tissue-Specific Delivery of Enzymes for Treatment of Lysosomal Diseases

Katherine Cygnar, Ph.D., Staff Scientist, Genome Engineering Tech, Regeneron Pharmaceuticals

2:20 Gene Discovery Efforts in Pediatric Patients with Undiagnosed Conditions

Pankaj B. Agrawal, M.D., MMSC, Geneticist and Medical Director, Gene Discovery Core, Manton Center for Orphan Disease Research, Boston Children's Hospital; Assistant Professor, Pediatrics, Harvard Medical School    

Gene discovery core of the Manton Center at Boston Children's Hospital is focused on identifying genes for rare disease patients with unexplained conditions. We have identified several novel genes using latest sequencing technologies and confirmed pathogenicity using cellular and animal models thereby advancing science and helping those families. This needs collaboration between clinicians, genetic counselors, bioinformaticians and basic scientists, long-term goals being to find appropriate therapies.

2:50 Leveraging Cancer Genomics to Identify Targetable Mutations in Rare Cancer Types

Ryan Hartmaier, Ph.D., Senior Scientist, Cancer Genomics, Foundation Medicine, Inc.

The scarcity of genomic data in rare cancer types is a challenge for identifying and developing effective therapeutics. Here we explore the genomics of rare cancer types for novel, potentially druggable genomic alterations. Further, we surveyed the spectrum of known clinically relevant genomic changes to identify potential opportunities for broader utility of approved targeted agents in novel cancer types.

3:20 Familial Amyloid Polyneuropathy: How a Genetic Disease Informs Drug Discovery

Christine Bulawa, Ph.D., Senior Director, Rare Disease Research Unit, Pfizer

This talk will present a case study of drug development for familial amyloid polyneuropathy (FAP), a disease caused by mutations in the circulating protein transthyretin. Insights gleaned from biophysical studies of transthyretin and clinical observations of FAP patients led to the therapeutic strategy of native state stabilization and ultimately to development of tafamidis, the first and only disease modifying therapy for an amyloid disease.

3:50 Close of Symposium

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English

Catalog

Celebrating 25 Years

Submit A Poster

View All Sponsors

View Media Partners



免费电子邮件通知服务